PEG-Interferon-α ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study.

doi:10.7399/fh.2015.39.1.8547

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

PEG-Interferon-α ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study.

Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria - 1 Jan 2015

Milara Javier, Outeda-Macias Maria, Aumente-Rubio M Dolores, Más-Serrano Patricio, Aldaz Azucena, Calvo M Victoria, García-Simón M Sergia, Martin-Barbero Marisa, Padullés-Zamora Núria, Schoenenberger Juan Antonio, Saavedra-Aldrich Marianne, Tévar-Alfonso Enrique, Saval Ana, Pastor-Clerigues Alfonso, García Marta, Margusino-Framiñan Luis, Montero-Alvarez Jose Luis, Merino Esperanza, Herrero Jose Ignacio, Beunza Mónica, Conesa-Zamora Pablo, Gimenez-Manzorro Alvaro, Comas-Sugrañes Dolors, Cano-Marron Manuel, Jiménez-Mutiloa Elena, Díaz-Ruíz Pilar, Cortijo Julio

Abstract excerpt

OBJECTIVE: Dual PEGylated interferon-α (PEG-IFN) and ribavirin therapy has been the main hepatitis C virus (HCV) treatment of the last decade. Current direct-acting antiviral agents have improved the outcome of therapy but also have increased the cost and management complexity of treatment. The c...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Antiviral Agents

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Hepatitis C

Share to Interferon-alpha

Share to Pharmacogenetics

Share to Polyethylene Glycols

Share to Ribavirin

Share to Spain

Share to Viral Load

Source

Open in PubMed

Identifiers

PMID: 25680433
DOI: 10.7399/fh.2015.39.1.8547

Genes

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026. Prepared record publication-25680433-2026-09-04.2. Manifest publication-graph-cohort-2026-09-04.2.

Source receipt: PubMed via Helena Literature Corpus, retrieved 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

PEG-Interferon-α ribavirin-induced HCV viral clearance: a pharmacogenetic multicenter Spanish study.PMID 25680433Read ↗

Meta-analysis: IL28B polymorphisms predict sustained viral response in HCV patients treated with pegylated interferon-α and ribavirin.Semantic proximity Read ↗

Pharmacogenetics of hepatitis C: transition from interferon-based therapies to direct-acting antiviral agentsSemantic proximity Read ↗

IL28B polymorphisms predict the response to chronic hepatitis C virus infection treatment in a Mexican population.Semantic proximity Read ↗

Genetic variation in interleukin-28B predicts SVR in hepatitis C genotype 1 Argentine patients treated with PEG IFN and ribavirin.Semantic proximity Read ↗

IFN-λ gene polymorphisms as predictive factors in chronic hepatitis C treatment-naive patients without access to protease inhibitors.Semantic proximity Read ↗

Clinical Pharmacogenetics Implementation Consortium (CPIC) guidelines for IFNL3 (IL28B) genotype and PEG interferon-α-based regimens.Semantic proximity Read ↗

Negative predictive value of IL28B, SLC28A2, and CYP27B1 SNPs and low RBV plasma exposure for therapeutic response to PEG/IFN-RBV treatment.Semantic proximity Read ↗

Interferon-lambda 3 and 4 Polymorphisms Increase Sustained Virological Responses and Regulate Innate Immunity in Antiviral Therapy With Pegylated Interferon-Alpha.Semantic proximity Read ↗

Treatment with PEG-IFN and ribavirin in patients with chronic hepatitis C, low grade of hepatic fibrosis, genotype 1 and 4 and favorable IFNL3 genotype: A pharmacogenetic prospective study.Semantic proximity Read ↗

Predictive value of interferon-lambda gene polymorphisms for treatment response in chronic hepatitis C.Semantic proximity Read ↗

The role of viral and host genetics in natural history and treatment of chronic HCV infection.Semantic proximity Read ↗

Impact of the peginterferon-α 2a and ribavirin plasma levels on viral kinetics and sustained virological response in genotype 1 HCV/HIV-co-infected patients with the unfavourable non-CC IL28B genotypes.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.